Appili Therapeutics Inc
APLIF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$926.56K
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $926,563.00 |
|---|---|
| Enterprise Value | $14.11 Million |
| Earnings per Share | $-0.03 |
| Beta | -0.21 |
| Outstanding Shares | 132,366,120 |
Return
| Return on Equity | 24.61% |
|---|---|
| Return on Assets | -361.50% |
| Return on Invested Capital | 31.88% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | -0.01 |
| Enterprise Value to Revenue | 37.26 |
| Enterprise Value to EBIT | -2.41 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.94 |
| Debt to Equity | -0.7 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.04
Consensus analyst estimateRevenue Estimate
$82,997
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.04
Consensus analyst estimateRevenue Estimate
$84,348
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Appili Therapeutics Inc
7 employees
CEO: Don Cilla
Appili Therapeutics, Inc. operates as a biopharmaceutical company, which acquires and develops novel treatments targeting unmet needs in infectious disease. It focuses on building and advancing a diverse portfolio of anti-infective progr...